Compile Data Set for Download or QSAR
Report error Found 51 Enz. Inhib. hit(s) with all data for entry = 12395
TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700422(US20240336610, Example 28 | US20240336610, GDI-028)
Affinity DataIC50: 2.40nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700421(US20240336610, Example 27 | US20240336610, GDI-027)
Affinity DataIC50: 7.60nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700417(US20240336610, Example 23 | US20240336610, GDI-023)
Affinity DataIC50: 15nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700420(US20240336610, Example 26 | US20240336610, GDI-026)
Affinity DataIC50: 17nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700416(US20240336610, Example 22 | US20240336610, GDI-022)
Affinity DataIC50: 17nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700429(US20240336610, Example 35 | US20240336610, GDI-035)
Affinity DataIC50: 17nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700424(US20240336610, Example 30 | US20240336610, GDI-030)
Affinity DataIC50: 18nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700419(US20240336610, Example 25 | US20240336610, GDI-025)
Affinity DataIC50: 19nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700415(US20240336610, Example 21 | US20240336610, GDI-021)
Affinity DataIC50: 19nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700414(US20240336610, Example 20 | US20240336610, GDI-020)
Affinity DataIC50: 19nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700430(US20240336610, Example 36 | US20240336610, GDI-036)
Affinity DataIC50: 20nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700430(US20240336610, Example 36 | US20240336610, GDI-036)
Affinity DataEC50:  20nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700413(US20240336610, Example 19 | US20240336610, GDI-019)
Affinity DataIC50: 22nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700423(US20240336610, Example 29 | US20240336610, GDI-029)
Affinity DataIC50: 23nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700406(US20240336610, Example 12 | US20240336610, GDI-012)
Affinity DataIC50: 24nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700395(US20240336610, Example 1 | US20240336610, GDI-001 ...)
Affinity DataIC50: 27nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700400(US20240336610, Example 6 | US20240336610, GDI-006)
Affinity DataEC50:  28nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700426(US20240336610, Example 32 | US20240336610, GDI-032)
Affinity DataIC50: 28nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700400(US20240336610, Example 6 | US20240336610, GDI-006)
Affinity DataIC50: 28nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700431(US20240336610, Example 37 | US20240336610, GDI-037)
Affinity DataEC50:  30nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700410(US20240336610, Example 16 | US20240336610, GDI-016)
Affinity DataIC50: 31nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700410(US20240336610, Example 16 | US20240336610, GDI-016)
Affinity DataEC50:  32nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700402(US20240336610, Example 8 | US20240336610, GDI-008)
Affinity DataIC50: 37nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700431(US20240336610, Example 37 | US20240336610, GDI-037)
Affinity DataIC50: 40nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700411(US20240336610, Example 17 | US20240336610, GDI-017)
Affinity DataIC50: 46nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700408(US20240336610, Example 14 | US20240336610, GDI-014)
Affinity DataIC50: 46nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700397(US20240336610, Example 3 | US20240336610, GDI-003)
Affinity DataIC50: 50nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700403(US20240336610, Example 9 | US20240336610, GDI-009)
Affinity DataIC50: 53nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700427(US20240336610, Example 33 | US20240336610, GDI-033)
Affinity DataIC50: 56nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700428(US20240336610, Example 34 | US20240336610, GDI-034)
Affinity DataIC50: 62nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700405(US20240336610, Example 11 | US20240336610, GDI-011)
Affinity DataIC50: 78nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700395(US20240336610, Example 1 | US20240336610, GDI-001 ...)
Affinity DataIC50: 80nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700399(US20240336610, Example 5 | US20240336610, GDI-005)
Affinity DataIC50: 80nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700425(US20240336610, Example 31 | US20240336610, GDI-031)
Affinity DataIC50: 100nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700412(US20240336610, Example 18 | US20240336610, GDI-018)
Affinity DataIC50: 110nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700399(US20240336610, Example 5 | US20240336610, GDI-005)
Affinity DataEC50:  117nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700409(US20240336610, Example 15 | US20240336610, GDI-015)
Affinity DataIC50: 120nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700401(US20240336610, Example 7 | US20240336610, GDI-007)
Affinity DataIC50: 170nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700396(US20240336610, Example 2 | US20240336610, GDI-002)
Affinity DataIC50: 320nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700404(US20240336610, Example 10 | US20240336610, GDI-010)
Affinity DataIC50: 330nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700407(US20240336610, Example 13 | US20240336610, GDI-013)
Affinity DataIC50: 340nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700402(US20240336610, Example 8 | US20240336610, GDI-008)
Affinity DataEC50:  417nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700395(US20240336610, Example 1 | US20240336610, GDI-001 ...)
Affinity DataEC50:  462nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700401(US20240336610, Example 7 | US20240336610, GDI-007)
Affinity DataEC50:  512nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700395(US20240336610, Example 1 | US20240336610, GDI-001 ...)
Affinity DataEC50:  547nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700405(US20240336610, Example 11 | US20240336610, GDI-011)
Affinity DataEC50:  613nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700411(US20240336610, Example 17 | US20240336610, GDI-017)
Affinity DataEC50:  660nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700397(US20240336610, Example 3 | US20240336610, GDI-003)
Affinity DataEC50:  1.25E+3nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700404(US20240336610, Example 10 | US20240336610, GDI-010)
Affinity DataEC50:  5.72E+3nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
The Global Health Drug Discovery Institute

US Patent
LigandPNGBDBM700396(US20240336610, Example 2 | US20240336610, GDI-002)
Affinity DataEC50:  7.86E+3nMAssay Description:An inhibition test was conducted using 200 nM recombinant SARS-CoV-2 main protease and 15 μM fluorescent substrate (Dabcyl-TSAVL QSGFRK-Glu (EDA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

Displayed 1 to 50 (of 51 total ) | Next | Last >>
Jump to: